Literature DB >> 30444956

Mechanisms of lymphatic system-specific viral replication and its potential role in autoimmune disease.

S-K Friedrich1, P A Lang2, J Friebus-Kardash1, V Duhan1, J Bezgovsek1, K S Lang1.   

Abstract

Viral infections can be fatal because of the direct cytopathic effects of the virus or the induction of a strong, uncontrolled inflammatory response. Virus and host intrinsic characteristics strongly modulate the outcome of viral infections. Recently we determined the circumstances under which enhanced replication of virus within the lymphoid tissue is beneficial for the outcome of a disease. This enforced viral replication promotes anti-viral immune activation and, counterintuitively, accelerates virus control. In this review we summarize the mechanisms that contribute to enforced viral replication. Antigen-presenting cells and CD169+ macrophages exhibit enforced viral replication after infection with the model viruses lymphocytic choriomeningitis virus (LCMV) and vesicular stomatitis virus (VSV). Ubiquitin-specific peptidase 18 (Usp18), an endogenous type I interferon blocker in CD169+ macrophages, has been identified as a proviral gene, as are B cell activating factor (BAFF) and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Lymphotoxins (LT) strongly enhance viral replication in the spleen and lymph nodes. All these factors modulate splenic architecture and thereby promote the development of CD169+ macrophages. Tumor necrosis factor alpha (TNF-α) and nuclear factor kappa-light-chain-enhancer of activated B cell signaling (NF-κB) have been found to promote the survival of infected CD169+ macrophages, thereby similarly promoting enforced viral replication. Association of autoimmune disease with infections is evident from (1) autoimmune phenomena described during a chronic virus infection; (2) onset of autoimmune disease simultaneous to viral infections; and (3) experimental evidence. Involvement of virus infection during onset of type I diabetes is strongly evident. Epstein-Bar virus (EBV) infection was discussed to be involved in the pathogenesis of systemic lupus erythematosus. In conclusion, several mechanisms promote viral replication in secondary lymphatic organs. Identifying such factors in humans is a challenge for future studies.
© 2018 British Society for Immunology.

Entities:  

Keywords:  CD169+ macrophages; autoimmune; enforced viral replication; interferon; virus

Mesh:

Year:  2019        PMID: 30444956      PMCID: PMC6300653          DOI: 10.1111/cei.13241

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  110 in total

1.  Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus.

Authors:  Nadine Honke; Namir Shaabani; Giuseppe Cadeddu; Ursula R Sorg; Dong-Er Zhang; Mirko Trilling; Karin Klingel; Martina Sauter; Reinhard Kandolf; Nicole Gailus; Nico van Rooijen; Christoph Burkart; Stephan E Baldus; Melanie Grusdat; Max Löhning; Hartmut Hengel; Klaus Pfeffer; Masato Tanaka; Dieter Häussinger; Mike Recher; Philipp A Lang; Karl S Lang
Journal:  Nat Immunol       Date:  2011-11-20       Impact factor: 25.606

2.  B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity.

Authors:  E Ashley Moseman; Matteo Iannacone; Lidia Bosurgi; Elena Tonti; Nicolas Chevrier; Alexei Tumanov; Yang-Xin Fu; Nir Hacohen; Ulrich H von Andrian
Journal:  Immunity       Date:  2012-03-01       Impact factor: 31.745

Review 3.  Type-I interferons and systemic lupus erythematosus.

Authors:  Sophie Koutouzov; Alexis Mathian; Ali Dalloul
Journal:  Autoimmun Rev       Date:  2006-06-27       Impact factor: 9.754

4.  Restoration of tolerance in lupus by targeted inhibitory receptor expression.

Authors:  Tracy L McGaha; Brian Sorrentino; Jeffrey V Ravetch
Journal:  Science       Date:  2005-01-28       Impact factor: 47.728

5.  Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.

Authors:  H Faden; J F Modlin; M L Thoms; A M McBean; M B Ferdon; P L Ogra
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

7.  Expression of lymphotoxin beta governs immunity at two distinct levels.

Authors:  Tobias Junt; Alexei V Tumanov; Nicola Harris; Mathias Heikenwalder; Nicolas Zeller; Dmitry V Kuprash; Adriano Aguzzi; Burkhard Ludewig; Sergei A Nedospasov; Rolf M Zinkernagel
Journal:  Eur J Immunol       Date:  2006-08       Impact factor: 5.532

Review 8.  The role of the innate immune response in autoimmune disease.

Authors:  Karl S Lang; Annika Burow; Michael Kurrer; Philipp A Lang; Mike Recher
Journal:  J Autoimmun       Date:  2007-09-29       Impact factor: 7.094

Review 9.  Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus.

Authors:  Tiffany Caza; Zachary Oaks; Andras Perl
Journal:  Int Rev Immunol       Date:  2014-01-28       Impact factor: 5.311

10.  Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes.

Authors:  Sergey Nejentsev; Neil Walker; David Riches; Michael Egholm; John A Todd
Journal:  Science       Date:  2009-03-05       Impact factor: 47.728

View more
  2 in total

1.  Pathogen infection and autoimmune disease.

Authors:  U Christen
Journal:  Clin Exp Immunol       Date:  2019-01       Impact factor: 4.330

2.  Innate Immune Modulation Induced by EBV Lytic Infection Promotes Endothelial Cell Inflammation and Vascular Injury in Scleroderma.

Authors:  Antonella Farina; Edoardo Rosato; Michael York; Benjamin E Gewurz; Maria Trojanowska; Giuseppina Alessandra Farina
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.